Abstract
Background
Drugs with anticholinergic effects are associated with adverse events such as delirium and falls as well as cognitive decline and loss of independence.
Objective
The aim of the study was to evaluate the association between anticholinergic burden and both cognitive and functional status, according to the hypothesis that the cumulative anticholinergic burden, as measured by the Anticholinergic Cognitive Burden (ACB) Scale and Anticholinergic Risk Scale (ARS), increases the risk of cognitive decline and impairs activities of daily living.
Methods
This cross-sectional, prospective study (3-month telephone follow-up) was conducted in 66 Italian internal medicine and geriatric wards participating in the Registry of Polytherapies SIMI (Società Italiana di Medicina Interna) (REPOSI) study during 2010. The sample included 1,380 inpatients aged 65 years or older. Cognitive status was rated with the Short Blessed Test (SBT) and physical function with the Barthel Index. Each patient’s anticholinergic burden was evaluated using the ACB and ARS scores.
Results
The mean SBT score for patients treated with anticholinergic drugs was higher than that for patients receiving no anticholinergic medications as also indicated by the ACB scale, even after adjustment for age, sex, education, stroke and transient ischaemic attack [9.2 (95 % CI 8.6–9.9) vs. 8.5 (95 % CI 7.8–9.2); p = 0.05]. There was a dose–response relationship between total ACB score and cognitive impairment. Patients identified by the ARS had more severe cognitive and physical impairment than patients identified by the ACB scale, and the dose–response relationship between this score and ability to perform activities of daily living was clear. No correlation was found with length of hospital stay.
Conclusions
Drugs with anticholinergic properties identified by the ACB scale and ARS are associated with worse cognitive and functional performance in elderly patients. The ACB scale might permit a rapid identification of drugs potentially associated with cognitive impairment in a dose–response pattern, but the ARS is better at rating activities of daily living.
Similar content being viewed by others
References
Veehof LJG, Stewart RE, Haaijer-Raskamp FM, et al. The development of polypharmacy. A longitudinal study. Fam Pract. 2000;17:261–7.
Gurwitz JH. Polypharmacy. A new paradigm for quality drug therapy in the elderly? Arch Intern Med. 2004;164:1957–9.
Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother. 2007;5:345–51.
Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85:86–98.
Steinman MA, Landefeld CS, Rosenthal GE, et al. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54:1516–23.
Koh Y, Kutty FBM, Li SC. Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender. Ther Clin Risk Manag. 2005;1:39–48.
Lund BC, Camahan RM, Egge JA, et al. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother. 2010. doi:10.1345/aph.1M657.
Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbidity. 2011;1:28–44.
Flacker JM, Cummings V, Mach JR Jr, et al. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry. 1998;6(1):31–41.
Tune LE. Anticholinergic effects of medication in elderly patients. J Clin Psychiatry. 2001;62(suppl 21):11–4.
Hanlon JT, Schamder KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc. 2002;50:26–34.
Boustani M, Hall KS, Lane KA, et al. The association between cognition and histamine-2 receptor antagonists in African Americans. J Am Geriatr Soc. 2007;55:1248–53.
Castelino RL, Bajorek BV, Chen TF. Targeting suboptimal prescribing in the elderly: a review of the impact of pharmacy services. Ann Pharmacother. 2009;43:1096–106.
Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. Neurology. 2010;75:152–9.
Carriere I, Fourrier-Reglat A, Dartigues JF, et al. Drugs with anticholinergic properties, cognitive decline, dementia in an elderly general population-the 3-City study. Arch Intern Med. 2009;169:1317–24.
Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch Gen Psychiatry. 2003;60(2):198–203.
Chew ML, Mulsant BH, Pollock BG. Serum anticholinergic activity and cognition in patients with moderate-to-severe dementia. Am J Geriatr Psychiatry. 2005;13(6):535–8.
Lechevallier-Michel N, Molimard M, Dartigues JF, et al. Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID study. Br J Clin Pharmacol. 2005;59(2):143–51.
Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. J Am Geriatr Soc. 2002;50(5):836–42.
Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161(8):1099–105.
Moore AR, O’Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging. 1999;15(1):15–28.
Aizenberg D, Sigler M, Weizman A, et al. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int Psychogeriatr. 2002;14(3):307–10.
Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455–9.
Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail elderly population. Clin Pharmacol Ther. 2007;81(2):235–41.
Low LF, Anstey KJ, Sachdev P. Use of medication with anticholinergic properties and cognitive function in a young-old community sample. Int Geriatr Psychiaty. 2009;24:578–84.
Atkin PA, Veitch PC, Veitch EM, et al. The epidemiology of serious adverse drug reactions among the elderly. Drugs Aging. 1999;14(2):141–52.
Hutchinson TA, Flegel KM, Kramer MS, et al. Frequency, severity and risk factors for adverse drug reactions in adult out-patients: a prospective study. J Chronic Dis. 1986;39(7):533–42.
Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older person. Arch Intern Med. 2008;168(5):508–13.
Buostani M, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–20.
Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22(6):597–602.
Marengoni A, Corrao S, Nobili A, et al. In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. Int J Geriatr Psychiatry. 2011;26(9):930–6.
Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med. 2011;22(2):205–10.
Nobili A, Licata G, Salerno F, et al. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. Eur J Clin Pharmacol. 2011;67(5):507–19.
Marcucci M, Iorio A, Nobili A, et al. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. Eur J Intern Med. 2010;21(6):516–23.
Marengoni A, Corrao S, Nobili A, et al. The participating units and co‐authors are listed in the Appendix. In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. Int J Geriatr Psychiatry. 2010.
Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc. 1995;43(2):130–7.
Shah S, Vanclay F, Cooper B. Improving the sensitivity of the Barthel Index for stroke rehabilitation. J Clin Epidemiol. 1989;42(8):703–9.
Katzman R, Brown T, Fuld P, et al. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983;140(6):734–9.
Hickie C, Snowdon J. Depression scales for the elderly: GDS, Gilleard, Zung. Clin Gerontol. 1987;6(3):51–3.
Carnahan RM, et al. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: association with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.
Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989;39(9):1159–65.
Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59(8):1477–83.
Sunderland T, Tariot PN, Cohen RM, et al. Anticholinergic sensitivity in patients with dementia of the Alzheimer’s type and age-matched controls: a dose response study. Arch Gen Psychiatry. 1987;44:418–26.
Fox C, Livingstone G, Maidment I, et al. The impact of anticholinergic burden in Alzheimer’s dementia-the laser AD study. Age Ageing. 2011;40:730–5.
Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716–24.
Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Persons’ Prescriptions) and START (Screening Tool to Alert Doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.
Chang CB, Chan DC. Comparison of published explicit criteria for potentially inappropriate medications in older adults. Drugs Aging. 2010;27(12):947–57.
Morris JC, Edland S, Clark C, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part V. Rates of cognitive change in the longitudinal assessment of probable Alzheimer’s disease. Neurology. 1993;43:2457–65.
Torijesen I. Anticholinergic effects of common drugs are associated with increased mortality in over 65s. BMJ. 2011;342:d3514.
Campbell N, Perkins A, Hui S, Khan B, Boustani M. Association between prescribing of anticholinergic medications and incident delirium: a cohort study. J Am Geriatr Soc. 2011;59(Suppl 2):S277–81. doi:10.1111/j.1532-5415.2011.03676.x.
Flacker JM, Wei JY. Endogenous anticholinergic substances may exist during acute illness in elderly medical patients. J Gerontol A Biol Sci Med Sci. 2001;56(6):M353–5.
Acknowledgments
The REPOSI study is a network of Italian internal medicine hospital wards that, voluntarily and without any financial support, agreed to participate in data collection during the 4 index weeks. All authors had full access to all data and take responsibility for its integrity and the accuracy of the data analysis. All authors reviewed the manuscript and contributed to the interpretation of results. The authors have no conflict of interest. We are grateful to Judith Baggott for editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
On behalf of REPOSI Investigators.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Pasina, L., Djade, C.D., Lucca, U. et al. Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale. Drugs Aging 30, 103–112 (2013). https://doi.org/10.1007/s40266-012-0044-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40266-012-0044-x